PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Boron Compounds”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

Three-coordinate organoboron compounds BAr2R (Ar = mesityl, R = 7-azaindolyl- or 2,2'-dipyridylamino-functionalized aryl or thienyl) for electroluminescent devices and supramolecular assembly.

Eight novel three-coordinate boron compounds with the general formula BAr(2)L, in which Ar is mesityl and L is a 7-azaindolyl- or a 2,2'-dipyridylamino-functionalized aryl or thienyl ligand, have been synthesized by Suzuki coupling, Ullmann condensation methods, or simple substitution reactions (L = p-(2,2'-dipyridylamino)phenyl, 1; p-(2,2'-dipyridylamino)biphenyl, 2; p-(7-azaindolyl)phenyl, 3; p-(7-azaindolyl)biphenyl, 4; 3,5-bis(2,2'-dipyridylamino)phenyl, 5; 3,5-bis(7-azaindolyl)phenyl, 6; p-[3,5-bis(2,2'-dipyridylamino)phenyl]phenyl, 7; 5-[p-(2,2'-dipyridylamino)phenyl]-2-thienyl, 8). The structures of 1, 3, and 5-7 have been determined by X-ray diffraction analyses. These new boron compounds are bright blue emitters. Electroluminescent devices using compound 2 or 8 as the emitter and the electron-transport layer have been successfully fabricated. Molecular orbital calculations (Gaussian 98) have established that the blue emission of compounds 1-8 originates from charge transfer between the pi orbital of the ligand L and the p(pi) orbital of the boron center. The ability of these boron compounds to bind to metal centers to form supramolecular assemblies was demonstrated by treatment of compound 2 with Zn(O(2)CCF(3))(2), which generated a 1:1 chelate complex [2.Zn(O(2)CCF(3))(2)] (10), and also by treatment of compound 4 with AgNO(3), yielding a 2:1 coordination compound [(4)(2).Ag(NO(3))] (11). In the solid state, compounds 10 and 11 form interesting head-to-head and tail-to-tail extended structures that host solvent molecules such as benzene.

Journal Article↗

Preparation and Characterization of Halogen-Boron-Phosphorus Compounds. X-ray Crystal Structures of X(3)B.P(SiMe(3))(3) and [X(2)BP(SiMe(3))(2)](2) (X = Cl, Br).

The 1:1 mole ratio reactions of boron trihalides (BX(3)) with tris(trimethylsilyl)phosphine [P(SiMe(3))(3)] produced 1:1 Lewis acid/base adducts [X(3)B.P(SiMe(3))(3), X = Cl (1), Br (2), I (5)]. Analogous 1:1 mole ratio reactions of these boron trihalides with lithium bis(trimethylsilyl)phosphide [LiP(SiMe(3))(2)] produced dimeric boron-phosphorus ring compounds {[X(2)BP(SiMe(3))(2)](2), X = Br (3), Cl (4)}. X-ray crystallographic studies were successfully conducted on compounds 1-4. Compound 1 crystallized in the orthorhombic space group Pbca, with a = 13.420(3) Å, b = 17.044(5) Å, c = 21.731(7) Å, V = 4970.6(25) Å(3), and D(calc) = 1.229 g cm(-3) for Z = 8; the B-P bond length was 2.022(9) Å, Compound 2 crystallized in the orthorhombic space group Pbca, with a = 13.581(6) Å, b = 17.106(7) Å, c = 22.021(9) Å, V = 5116(4) Å(3), and D(calc) = 1.540 g cm(-3) for Z = 8; the B-P bond length was 2.00(2) Å. Compound 3 crystallized in the monoclinic space group P2(1)/n, with a = 9.063(5) Å, b = 16.391(8) Å, c = 9.331(4) Å, V = 1379.2(12) Å(3), and D(calc) = 1.676 g cm(-3) for Z = 2; the B-P bond length was 2.023(10) Å. Compound 4 crystallized in the monoclinic space group P2(1)/n, with a = 9.143(5) Å, b = 16.021(8) Å, c = 9.170(4) Å, V = 1342.2(11) Å(3), and D(calc) = 1.282 g cm(-3) for Z = 2; the B-P bond length was 2.025(3) Å. Thermal decomposition studies were performed on compounds 1-4, yielding colored powders with boron:phosphorus ratios greater than 1:1 and significant C and H contamination indicated by elemental analyses.

Journal Article↗

Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy.

Boron neutron capture therapy (BNCT) depends on the selective delivery of a sufficient number of (10)B atoms to tumor cells to sustain a lethal (10)B(n,alpha)(7)Li reaction. Expression of FR frequently is amplified among human tumors. The goal of the present study was to investigate folate receptor (FR)-targeted liposomes as potential carriers for a series of boron-containing agents. Two highly ionized boron compounds, Na(2)[B(12)H(11)SH] and Na(3) (B(20)H(17)NH(3)), were incorporated into liposomes by passive loading with encapsulation efficiencies of 6% and 15%, respectively. In addition, five weakly basic boronated polyamines were investigated. Two were the spermidine derivatives: N(5)-(4-carboranylbutyl)spermidine.3HCl (SPD-5), N(5)-[4-(2-aminoethyl-o-carboranyl)butyl]spermidine.4HCl (ASPD-5). Three were the spermine derivatives: N(5)-(4-carboranylbutyl)spermine.4HCl (SPM-5), N(5)-[4-(2-aminoethyl-o-carboranyl)butyl]spermine.5HCl (ASPM-5), and N(5),N(10)-bis(4-carboranylbutyl)spermine.4 HCl (SPM-5,10). These were incorporated into liposomes by a pH-gradient-driven remote-loading method with varying loading efficiencies, which were influenced by the specific trapping agent and the structure of the boron compound. Greater loading efficiencies were obtained with lower molecular weight boron derivatives, using ammonium sulfate as the trapping agent, compared to those obtained with sodium citrate. The in vitro uptake of folate-derivatized, boronated liposomes was investigated using human KB squamous epithelial cancer cells, which have amplified FR expression. Higher cellular boron uptake (up to 1584 microg per 10(9) cells) was observed with FR-targeted liposomes than with nontargeted control liposomes (up to 154 microg per 10(9) cells), irrespective of the chemical form of the boron and the method used for liposomal preparation. KB cell binding of the FR-targeted liposomes was saturable and could be blocked by 1 mM free folic acid. Our findings suggest that further evaluation of FR-targeted liposomes is warranted to assess their potential as boron carriers for neutron capture therapy.

Boron Compounds↗

[Boron neutron capture a a new radiotherapy model].

The boron neutron capture therapy is based on the reaction occurring with certain probability, if a thermal neutron meets the boron 10 isotope. The low energy slow neutron is captured by the nucleus and it disintegrates into Li-nucleus and He-nucleus (alpha particle). If this physical reaction occurs in a living cell that will be destroyed. If the boron neutron capture reaction could be achieved selectively in malignant cells of tumor patients, that could be an effective therapeutical modality to treat the locally growing cancers. For boron neutron capture therapy to be successful two basic conditions must be fulfilled, an appropriate neutron source must be available and the sufficient number of 10B must be delivered possibly selectively into the tumor cells by a boron compound. At present both part of this binary system are under intensive investigation, the development of the neutron source, the synthetisation and experimental testing of boron delivery agents. The development of the dosimetry, microdosimetry, the work out of the powerful tools of detection the cellular, subcellular 10B distribution, the continuous improvement of the planning system and the optimization of the boron neutron capture therapy are the main point of the research area on boron neutron capture therapy. Clinical studies and clinical application of boron neutron capture therapy are under way for the treatment of melanoma malignum and for brain tumors, with the two boron compound has been clinically tested up to now, in Japan, at two Centres in USA, and recently has been started in Europe. The authors give an overview about the principles of boron neutron capture therapy, about the result of the research on neutron sources and boron compounds, moreover about the possible application area of this new radiation modality.

Boron↗

New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells.

The toxicity and binding of the three new carborane based compounds: 2 (1,2-dicarba-closo-dodecaborane (12)-1(-yl-methoxy)-2-(3-amino-propyl))-1,3-propanediol, called DAC-1; 7-(3-amino-propyl)-7,8-dicarba-nido-undecarborate (-1) called ANC-1; and rac-1-(9-o-carboranyl)-nonyl-2-methyl-glycero-3- phosphocholine, called B-Et-11-OMe, were analyzed with cultured human glioma cells, U-343MGa, and mouse melanoma cells, B16, as biological models. The previously developed compound di-sodium undecahydro-mercapto-closo-dodecarborate (BSH), which is tested for therapy of malignant gliomas, was analyzed for comparison. In the toxicity tests the cells were exposed to the substances at cell culture medium concentrations in the range 0-50 ppm boron for 1 or 20 h and thereafter analyzed regarding growth. Growth-disturbing effects were seen for the two compounds DAC-1 and B-Et-11-OMe at the concentrations corresponding to 15 and 50 ppm boron, respectively. The compounds ANC-1 and BSH showed no growth-disturbing effects at the tested concentrations. In the binding tests, the cells were incubated for 20 h at about the highest compound concentrations that did not cause growth disturbances. The boron content in the cells was then determined by inductively coupled plasma-atomic emission spectrometry (ICP-AES) and in some cases ICP-mass spectrometry (ICP-MS). The most extensive binding was seen for DAC-1 and B-Et-11-OMe, which accumulated boron to about 100 and 60 times, respectively, compared with the concentration in the culture medium. The compound ANC-1 also accumulated boron in the cells but the boron could be easily washed out indicating no or only a weak binding. BSH did not accumulate. Further analysis should be made regarding biological properties such as intracellular compartmentalization, metabolic interference and tumor specificity of the compounds DAC-1 and B-Et-11-OMe.

Animals↗

[Superimposition alpha-autoradiography for basic study of neutron capture therapy (author's transl)].

Since Locher suggested the possibility of neutron capture therapy, a number of investigators have been making efforts to establish clinical application of this treatment. For success of this therapy one of the keys is to develop a proper boron compound with selective accumulation and high concentration in the tumor. So far, sodium mercaptoundecahydrododecaborate, Na2B12H11SH is the best candidate for this purpose with its high concentration and selectivity shown by chemical analysis. Nevertheless, histological study of boron uptake to know fine distribution in tissue is inevitable for evidence of effectiveness of clinical therapy. Cytological effects in neutron capture therapy largely depend on close association of B-10 with the tumor cell. B-10, being non-radioactive isotope, can not be used as a tracer for autoradiographical study of boron distribution in tissue. Instead, alpha particles produced by (n, alpha) reaction can be used for autoradiography which demonstrates not only location of boron in tissue but tracks by alpha particles expected to occur in actual neutron irradiation. Dielectric organic polymer has been calling attention for its ability to register heavy particles which was utilized for alpha autoradiography. Autoradiography by use of plastic film without nuclear emulsion has advantages; (1) simple procedures, (2) no darkroom needed, (3) a lower background obtainable, (4) little influence of temperature and moisture, (5) long standing material and so on. The disadvantage of this procedure is that tissue sections are easily damaged by strong alkalinity used for chemical etching. To solve this problem an overlapping histologic technique was worked out, permitting one to determine the relation of the heavy particle tracks to the intra and extracellular structures. Na2B12H11SH, a boron compound already in practical use, has been restudied by using this new technique. Autoradiograms showed favorable results with abundant alpha tracks over the tumor tissue in close relation to the cells and with very few tracks over the normal brain parenchyma. This technique is a useful means not only for further development of boron compounds but for other alpha emitters.

Animals↗

Long-term infusions of p-boronophenylalanine for boron neutron capture therapy: evaluation using rat brain tumor and spinal cord models.

Rat 9L gliosarcoma cells infiltrating the normal brain have been shown previously to accumulate only approximately 30% as much boron as the intact tumor after administration of the boronated amino acid p-boronophenylalanine (BPA). Long-term i.v. infusions of BPA were shown previously to increase the boron content of these infiltrating tumor cells significantly. Experiments to determine whether this improved BPA distribution into infiltrating tumor cells after a long-term i.v. infusion improves tumor control after BNCT in this brain tumor model and whether it has any deleterious effects in the response of the rat spinal cord to BNCT are the subjects of the present report. BPA was administered in a fructose solution at a dose of 650 mg BPA/kg by single i.p. injection or by i.v. infusion for 2 h or 6 h, at 330 mg BPA/kg h(-1). At 1 h after the end of either the 2-h or the 6-h infusion, the CNS:blood (10)B partition ratio was 0.9:1. At 3 h after the single i.p. injection, the ratio was 0.6:1. After spinal cord irradiations, the ED(50) for myeloparesis was 14.7 +/- 0.4 Gy after i.p. administration of BPA and 12.9 +/- 0.3 Gy in rats irradiated after a 6-h i.v. infusion of BPA; these values were significantly different (P < 0.001). After irradiation with 100 kVp X rays, the ED(50) was 18.6 +/- 0.1 Gy. The boron compound biological effectiveness (CBE) factors calculated for the boron neutron capture dose component were 1.2 +/- 0.1 for the i.p. BPA administration protocol and 1.5 +/- 0.1 after irradiation using the 6-h i.v. BPA infusion protocol (P < 0.05). In the rat 9L gliosarcoma brain tumor model, the blood boron concentrations at 1 h after the end of the 2-h infusion (330 mg BPA/kg h(-1); n = 15) or after the 6-h infusion (190 mg BPA/kg h(-1); n = 13) were 18.9 +/- 2.2 microg 10B/g and 20.7 +/- 1.8 microg 10B/g, respectively. The irradiation times were adjusted individually, based on the preirradiation blood sample, to deliver a predicted 50% tumor control dose of 8.2 Gy ( approximately 30 photon-equivalent Gy) to all tumors. In the present study, the long-term survival was approximately 50% and was not significantly different between the 2-h and the 6-h infusion groups. The mode of BPA administration and the time between administration and irradiation influence the 10B partition ratio between the CNS and the blood, which in turn influences the measured CBE factor. These findings underline the need for clinical biodistribution studies to be carried out to establish 10B partition ratios as a key component in the evaluation of modified administration protocols involving BPA.

Animals↗

Electrochemical oxidation of phenolic and other organic compounds at boron doped diamond electrodes for wastewater treatment: effect of mass transfer.

The paper presents the results of an experimental study on oxidation at boron doped diamond electrodes (BDD) of some phenolic compounds: phenol (PH), para-hydroxibenzoic acid (PHB), cathecole (CT), hydroquinone (HQ) are considered, singularly contained in aqueous solutions or in the presence of glucose (G), which was selected to represent the class of biodegradable compounds. Oxidation of benzoquinone (BQ) and maleic acid (MA), generally detected as intermediates products from phenol degradation, is also investigated. Great attention is paid to verify the feasibility of a selective process in which the oxidation is specifically addressed to the phenolic fraction up to non toxic intermediate products which are more biodegradable than the original phenols.

Biodegradation, Environmental↗

Therapeutic success of boron neutron capture therapy (BNCT) mediated by a chemically non-selective boron agent in an experimental model of oral cancer: a new paradigm in BNCT radiobiology.

The hypothesis of boron neutron capture therapy (BNCT) research has been that the short-range, high-linear energy transfer radiation produced by the capture of thermal neutrons by (10)B will potentially control tumor and spare normal tissue only if the boron compound selectively targets tumor tissue within the treatment volume. In a previous in vivo study of low-dose BNCT mediated by GB-10 (Na(2)(10)B(10)H(10)) alone or combined with boronophenylalanine (BPA) in the hamster cheek pouch oral cancer model that was primarily designed to evaluate safety and feasibility, we showed therapeutic effects but no associated normal tissue radiotoxicity. In the present study, we evaluated the response of tumor, precancerous and normal tissue to high-dose BNCT mediated by GB-10 alone or combined with BPA. Despite the fact that GB-10 does not target hamster cheek pouch tumors selectively, GB-10-BNCT induced a 70% overall tumor response with no damage to normal tissue. (GB-10+BPA)-BNCT induced a 93% overall tumor response with no normal tissue radiotoxicity. Light microscope analysis showed that GB-10-BNCT selectively damages tumor blood vessels, sparing precancerous and normal tissue vessels. In this case, selective tumor lethality would thus result from selective blood vessel damage rather than from selective uptake of the boron compound.

Animals↗

Penetration and binding of L- and D-carboranylalanine in human melanoma spheroids.

The principle of boron neutron capture therapy (BNCT) is that a cell-specific 10B-containing substance binds to tumour cells and irradiation with thermal neutrons is performed when the 10B concentration, in relation to the levels in critical normal tissues, is at a maximum. Some boron compounds have recently been proposed for BNCT of malignant melanomas; the synthesized L- and D- forms of carboranylalanine and the previously tested compound L-p-boronophenylalanine are candidates. Human melanoma, IGR1, spheroids were used as models of melanoma nodules in this study. The spheroids developed central necrosis when they were about 480 microns in diameter and the volume doubling time was 2.6 +/- 0.3 days. The tritiated thymidine labelling index decreased rapidly as a function of distance from the periphery and was, at a depth of 175 microns, close to zero. The penetration patterns showed, for L- and D-carboranylalanine and L-p-boronophenylalanine, a homogeneous distribution of 10B throughout the spheroids by 5 min. L-Carboranylalanine gave a more or less even binding of 10B throughout the spheroids and large amounts were present also in the central necrotic regions. D-Carboranylalanine also gave a homogeneous 10B binding in the viable cell layers while the binding in the central necrotic area was lower and a similar, but somewhat lower, binding was found for L-p-boronophenylalanine. Thus, there were no penetration barriers for the boron compounds and binding of 10B was found also in the deeper regions of the viable cell layers. The results showed that the new carboranylalanine compounds are of interest for further analysis, including toxicological and pharmacological studies in vivo.

Boron Compounds↗

In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficacy of the boron neutron capture agent DAC-1.

In boron neutron capture therapy (BNCT), 10B is delivered selectively to the tumour cells and the nuclide then forms high-LET radiation (4He2+ and 7Li3+) upon neutron capture. Today much research is focused on development of a variety of boron compounds aimed for BNCT. The compounds must be thoroughly analysed in preclinical tests regarding basic characteristics such as binding and subcellular distribution to enable accurate estimations of dose-modifying factors. DAC-1,2-[2-(3-amino-propyl)-1,2-dicarba-closo-dodecaboran (12)-1-yl-methoxy]- 1,3-propanediol was synthesized at our laboratories and the human colon carcinoma cells LS-174T were used as an in vitro model. The boron compound showed a remarkable intracellular accumulation, 20-100 times higher than the boron content in the culture medium, in cultured cells and was not removed by extensive washes. Approximately half of the boron taken up also remained within the cells for at least 4 days. The DAC-1 compound alone was not toxic at boron concentrations below 2.5 micrograms B/g. The intracellular distribution of the boron compound was investigated by subcellular fractionation experiments and low pH treatments. It is possible that DAC-1 binds to some intracellular molecules or to membranes connected with organelles in the cytoplasm or even to the inside of the outer cell membrane. Another possibility is that the compound, due to the somewhat lipophilic properties, is embedded in the membranes. Thermal neutron irradiations were carried out at the Brookhaven Medical Research Reactor (BMRR). At a survival level of 0.1, DAC-1 + thermal neutrons were about 10.5 times more effective in cell inactivation than the thermal neutrons alone. Monte Carlo calculations gave a mean value of the 10B-dependent specific energy, the dose, of 0.22 Gy. The total physical dose during irradiation of DAC-1-containing cells with a neutron fluence of 0.18 x 10(12) n/cm2 was 0.39 Gy. The dose-modifying factor, at survival level 0.1, when comparing irradiation with thermal neutrons with and without DAC-1 was 3.4, while the dose-modifying factor when comparing neutron irradiations of cells with DAC-1 and irradiation of the cells with 60Co-gamma was 7.3. The results are encouraging and in vivo tests of tissue distributions and tumour uptake should now be carried out.

Biological Availability↗

Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.

Boron neutron capture therapy (BNCT) is a unique radiation therapy in which boron compounds are trapped into tumor cells. To determine the biodistribution of boronophenylalanine (BPA) in nude mice carrying oral squamous cell carcinoma (SCC), BPA was administered at a dose of 250 mg/kg body weight intraperitoneally. Two hours later, (10)B concentration in the tumor was 15.96 ppm and tumor/blood, tumor/tongue, tumor/skin and tumor/bone (10)B concentration ratios were 6.44, 4.19, 4.68 and 4.56, respectively. Two hours after the administration of borocaptate sodium (BSH) at a dose of 75 mg/kg body weight, (10)B concentration in the tumor was 3.61 ppm, and tumor/blood, tumor/tongue, tumor/skin and tumor/bone (10)B concentration ratios were 0.77, 1.05, 0.60 and 0.59, respectively. When cultured oral SCC cells were incubated with BPA or BSH for 2 h and then exposed to thermal neutrons, the proportion of survival cells that were capable of forming cell colonies decreased exponentially, depending on (10)B concentration. BPA-mediated BNCT was more efficient than BSH-mediated BNCT. Addition of boron compounds in the cell suspension during neutron irradiation enhanced the cell-killing effect of the neutrons. These results indicate that BPA is more selectively incorporated into human oral SCC as compared with normal oral tissues, and that both extra- and intra-cellular BPA contribute to the cell-killing effect of BNCT. BPA may be a useful boron carrier for BNCT in the treatment of advanced oral SCC.

Animals↗

Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy.

PURPOSE: This study was aimed at the in vitro evaluations of folate receptor (FR)-targeted liposomes as carriers for a lipophilic boron agent, K[nido-7-CH3(CH2)15-7,8-C2B9H11, in FR-overexpressing tumor cells for neutron capture therapy. METHODS: Large unilamellar vesicles (-200 nm in diameter) were prepared with the composition of egg PC/chol/K[nido-7-CH3(CH2)15-7,8-C2B9H11] (2:2:1, mol/mol), with an additional 0.5 mol % of folate-PEG-DSPE or PEG-DSPE added for the FR-targeted or nontargeted liposomal formulations, respectively. RESULTS: Boron-containing, FR-targeted liposomes readily bound to KB cells, an FR-overexpressing cell line, and were internalized via FR-mediated endocytosis. The boron uptake in cells treated with these liposomes was approximately 10 times greater compared with those treated with control liposomes. In contrast, FR-targeted and nontargeted liposomes showed no difference in boron delivery efficiency in F98 cells, which do not express the FR. The subcellular distribution of the boron compound in KB cells treated with the FR-targeted liposomes was investigated by cellular fractionation experiments, which showed that most of the boron compound was found in either the cytosol/endosomal or cell membrane fractions, indicating efficient internalization of the liposomal boron. CONCLUSION: FR-targeted liposomes incorporating the lipophilic boron agent, K[nido-7-CH3(CH2)15-7,8-C2B9H11], into its bilayer were capable of specific receptor binding and receptor-mediated endocytosis in cultured KB cells. Such liposomes warrant further investigations for use in neutron capture therapy.

Boron Compounds↗

Synthesis of Cage Compounds Containing Boron, Tin, and Phosphorus Atoms.

The 1:1 reactions of [((i)()Pr(2)N)BP(H)B(N(i)()Pr(2))PLi.DME] (1) and [(tmp)BP(H)B(tmp)PLi.DME] (2; tmp = 2,2,6,6-tetramethylpiperidino) with organylhalostannanes have been examined, and stannyl-substituted diphosphadiboretanes, (R(2)N)BP(H)B(NR(2))PSn(Cl)R'(2) (R(2)N = (i)()Pr(2)N, tmp; R' = Me, (t)()Bu) have been isolated and characterized. Dehydrohalogenation of these compounds with (t)()BuLi produced bicyclic cage compounds P(2)(R(2)NB)(2)SnR'(2) (R(2)N = (i)()Pr(2)N (9), tmp (8); R' = (t)()Bu) or an oligomer [-P(R(2)NB)(2)PSn(R'(2))-] (R(2)N = tmp; R' = Me). The 2:1 reactions of R'(2)SnCl(2) with 1 and 2 have been studied, and with a small R' group (Me) a disubstitution product, [HP(tmpB)(2)P](2)SnMe(2) (11), is obtained. With a larger R' group ((t)()Bu), cage products P(2)(tmpB)(2)Sn(t)()Bu(2) and P(2)((i)()Pr(2)NB)(2)Sn(t)()Bu(2) are isolated. The molecular structures of 8 and 9 have been determined by single crystal X-ray diffraction techniques, and these structures and their spectroscopic features are discussed in relation to other boron-phosphorus cage compounds.

Journal Article↗

Self-assembly of halogenated cobaltacarborane compounds: boron-assisted C--H...X--B hydrogen bonds?

Full structural characterisation and complete synthetic procedures for three monohalogenated cobaltacarborane compounds closo-[3-Co(eta5-C5H5)-8-X-1,2-C2B9H10] (X=Cl (1), Br (2), I (3)) and the dibromo derivative closo-[3-Co(eta5-C5H5)-8,9-Br2-1,2-C2B9H9] (4) are reported. The supramolecular structures of 1, 3, and 4 reveal the existence of intermolecular C--HX--B interactions. The role of these interactions has been investigated through a CSD search and subsequent analysis of the reported crystalline compounds. The results show that halogens become reasonably good hydrogen-bond acceptors when bonded to boron and, in this respect, are comparable in strength to metal-bound halogens.

Boron↗

Monocyclic boron carbonyls: novel aromatic compounds.

Monocyclic boron carbonyls, (BCO)nm, with 4n + 2 delocalized electrons are highly aromatic, as indicated by the computed nucleus independent chemical shift (NICS) and the computed energies for benzene analogue.

Journal Article↗

Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: synthesis and biological evaluation.

Three series of new boron-containing spermidine/spermine (SPD/SPM) analogues have been synthesized: N1- and N5-(4-carboranylbutyl) SPD/SPM derivatives (SPD-1, SPD-5, SPM-1, SPM-5); N1,N10-diethyl-N5-(4-carboranylbutyl)spermidine (DESPD-5), N1,N14-diethyl-N5-(4-carboranylbutyl)spermine (DESPM-5); and N5,N10-bis(4-carboranylbutyl)spermine (SPM-5,10). In vitro studies using rat F98 glioma cells have shown that these polyamines retain the ability to displace ethidium bromide from calf thymus DNA and are rapidly taken up by F98 glioma cells. However, their cytotoxicities, especially those with terminal N-substituted (SPD-1, SPM-1) boron compounds, are greater than those of SPD/SPM. Nevertheless, the groundwork has been created for a new class of boron-containing compounds that maybe useful for boron neutron capture therapy of tumors.

Animals↗

Synthesis, structures, and luminescent properties of phenol-pyridyl boron complexes.

Syntheses of the four mixed phenol-pyridine derivatives 1,6-bis(2-hydroxyphenyl)pyridyl boron naphthalene (1), 1,6-bis(2-hydroxy-5-methylphenyl)pyridyl boron naphthalene (2), 1,6-bis(2-hydroxyphenyl)pyridyl boron 2-methoxylbenzene (3), and 1,6-bis(2-hydroxy-5-methylphenyl)pyridyl boron 2-methoxylbenzene (4) are reported. The structures of the boron compounds 1, 3, and 4 were determined by single-crystal X-ray diffraction. The molecular packing is characterized by intermolecular pi...pi and hydrogen-bonding interactions. DSC analysis demonstrates that 1 and 2 have good thermal stability with higher glass transition temperatures (Tg) and melting points (Tm) than 3 and 4. Boron complexes 1-4 display bright blue luminescence in solution and the solid state. White and blue electroluminescent (EL) devices were fabricated successfully using these boron compounds.

Boron Compounds↗